MedTrace Logo

A Study Exploring Whooping Cough Protection in Children and Adults

NCT03697798 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2021-01-08

No results posted yet for this study

Summary

This study aims to investigate the effects of aP booster vaccination in children, young adults and elderly on the (long-term) immune response to B. pertussis in three European countries with a different epidemiological background and primary vaccination schedule for pertussis.

Conditions

  • Pertussis

Interventions

BIOLOGICAL

Boostrix®-IPV combination vaccine

A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.

Sponsors & Collaborators

  • National Institute for Public Health and the Environment (RIVM)

    collaborator OTHER_GOV

  • University of Turku

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Dr Marlies van Houten · Spaarne Hospital, Hoofddorp

  • Prof. dr. Jussi Mertsola · Turku University Hospital

  • Dr Dominic Kelly · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-18
Primary Completion
2020-01-14
Completion
2020-01-14

Countries

  • Finland
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697798 on ClinicalTrials.gov